Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Taiho Oncology, Inc.
University Health Network, Toronto
Brigham and Women's Hospital
Fred Hutchinson Cancer Center
OncoNano Medicine, Inc.
Immunitas Therapeutics
Washington University School of Medicine
ModernaTX, Inc.
Incyte Corporation
University of Exeter
RenJi Hospital
Intensity Therapeutics, Inc.
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
RAPT Therapeutics, Inc.
Massachusetts General Hospital
Cedars-Sinai Medical Center
Presage Biosciences
Eisai Inc.
Icahn School of Medicine at Mount Sinai
Rutgers, The State University of New Jersey
Eastern Cooperative Oncology Group
Seagen Inc.
Fate Therapeutics
Genzada Pharmaceuticals USA, Inc.
Blue Note Therapeutics
Presage Biosciences
Incyte Corporation
Celgene
University College, London
Institut Bergonié
Celgene
Case Comprehensive Cancer Center
Tocagen Inc.
University of Wisconsin, Madison
Tel-Aviv Sourasky Medical Center
Mayo Clinic
University of California, San Diego
Stanford University
Amgen
Lytix Biopharma AS
National Cancer Centre, Singapore
Wuxi No. 4 People's Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
AHS Cancer Control Alberta
Valerio Therapeutics
University of Chicago